<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acute viral encephalitis in children: Treatment and prevention
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acute viral encephalitis in children: Treatment and prevention
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acute viral encephalitis in children: Treatment and prevention
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hordur S Hardarson, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin Messacar, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas R Nordli, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carrie Armsby, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 05, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Encephalitis is inflammation of the brain parenchyma, manifest by neurologic dysfunction (eg, altered mental status, behavior, or personality; motor or sensory deficits; speech or movement disorders; seizure) and evidence of central nervous system inflammation (eg, cerebrospinal fluid pleocytosis and/or findings consistent with encephalitis on neuroimaging or electroencephalogram).
        </p>
        <p>
         The treatment and prevention of viral encephalitis in children will be discussed here. The pathogenesis, etiology, clinical manifestations, and diagnosis of viral encephalitis in children are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6043.html" rel="external">
          "Acute viral encephalitis in children: Pathogenesis, epidemiology, and etiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6042.html" rel="external">
          "Acute viral encephalitis in children: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2384584798">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Central nervous system (CNS) infections are described according to the site of infection:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Encephalitis
         </strong>
         – Encephalitis is defined as inflammation of the brain parenchyma and is manifested by signs of neurologic dysfunction lasting at least 24 hours. Characteristic clinical features include altered mental status (decreased level of consciousness, lethargy, personality change, unusual behavior), seizures, and/or focal neurologic signs, often accompanied by fever, headache, nausea, and vomiting [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6042.html" rel="external">
          "Acute viral encephalitis in children: Clinical manifestations and diagnosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Meningitis
         </strong>
         – Meningitis is inflammation of the meninges and is typically manifested by fever, headache, nausea, vomiting, photophobia, and stiff neck. (See
         <a class="medical medical_review" href="/z/d/html/5983.html" rel="external">
          "Viral meningitis in children: Clinical features and diagnosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rhombencephalitis
         </strong>
         – Rhombencephalitis, or brainstem encephalitis, is characterized by myoclonic jerks, tremor, ataxia, cranial nerve involvement, respiratory abnormalities, shock, and coma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myelitis
         </strong>
         – Myelitis is inflammation of the spinal cord and is characterized by weakness, paralysis, bowel and/or bladder dysfunction, and changes in tone and reflexes. (See
         <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">
          "Disorders affecting the spinal cord", section on 'Acute viral myelitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radiculitis
         </strong>
         – Radiculitis is inflammation of the nerve roots and is characterized by weakness, shooting pain, dysesthesia, and diminished reflexes.
        </p>
        <p>
        </p>
        <p>
         Some viruses cause less discrete manifestations of CNS infection and are described with broader terms:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Meningoencephalitis
         </strong>
         – Meningoencephalitis refers to CNS infection manifesting signs and symptoms consistent with inflammation of the meninges and brain parenchyma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Encephalomyelitis
         </strong>
         – Encephalomyelitis refers to CNS infection manifesting signs and symptoms consistent with inflammation of the brain parenchyma and spinal cord.
        </p>
        <p>
        </p>
        <p>
         Abnormal brain function distinguishes encephalitis from meningitis. The distinction between these entities is frequently blurred as both may be present concurrently; however, it is important to try to determine the presence of encephalitis because the likely causes may differ somewhat (
         <a class="graphic graphic_table graphicRef56505" href="/z/d/graphic/56505.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Encephalopathy
         </strong>
         – Encephalopathy is a disruption of brain function in the absence of a direct inflammatory process in brain parenchyma (eg, caused by metabolic disturbance, hypoxia, ischemia, drugs, intoxications, organ dysfunction, systemic infection). This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6154.html" rel="external">
          "Acute toxic-metabolic encephalopathy in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3746276164">
         <span class="h1">
          SUPPORTIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Encephalitis is an acute, life-threatening emergency, requiring prompt intervention. Assessment and management often are performed simultaneously (
         <a class="graphic graphic_table graphicRef51779" href="/z/d/graphic/51779.html" rel="external">
          table 2
         </a>
         ). Supportive care is a critical aspect of the treatment of encephalitis. Initial supportive care measures may include stabilization of cardiorespiratory status and treatment of seizures. (See
         <a class="medical medical_review" href="/z/d/html/6393.html" rel="external">
          "Initial assessment and stabilization of children with respiratory or circulatory compromise"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">
          "Management of convulsive status epilepticus in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3834697525">
         <span class="h2">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with severe encephalitis (ie, those with seizures, cardiorespiratory compromise, coma, or severe neurologic compromise) should be cared for in an intensive care unit with close monitoring, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiorespiratory status.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurologic status – The Glasgow coma scale (GCS) score (
         <a class="graphic graphic_table graphicRef59662" href="/z/d/graphic/59662.html" rel="external">
          table 3
         </a>
         ), although not specifically validated in patients with encephalitis, can be helpful in quantifying the level of consciousness and monitoring neurologic progression. Acute deterioration in the neurologic status (eg, new focal findings, loss of pupillary reactivity, acute decline in GCS) should prompt repeat neuroimaging to evaluate for cerebral edema, hemorrhage, or other acute changes. Repeat neuroimaging may also be warranted in patients who do not improve as expected over the initial days to weeks. Computed tomography is typically performed to evaluate acute changes, and magnetic resonance imaging is performed when more detailed diagnostic and prognostic information is desired.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluid balance and electrolytes – It is important to monitor fluid balance (eg, input, urine output, daily weight) and electrolyte status in patients with severe encephalitis, as is the case with all critically ill children. Hypovolemia (if present) should be addressed with appropriate volume expansion (eg, 20 mL/kg normal
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         bolus). Subsequent fluid management generally consists of isotonic maintenance intravenous (IV) fluids to maintain euvolemia. Fluid restriction is not typically necessary. Patients who have depressed mental status and those in whom airway reflexes are not intact are kept nil per os. Enteral feeding tubes are used to provide adequate nutrition in patients who are not able to feed by mouth. Parenteral nutrition is generally reserved for patients who are unable to resume enteral feeding after one week. (See
         <a class="medical medical_review" href="/z/d/html/6122.html" rel="external">
          "Maintenance intravenous fluid therapy in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15643.html" rel="external">
          "Overview of enteral nutrition in infants and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15634.html" rel="external">
          "Parenteral nutrition in infants and children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2070068841">
         <span class="h2">
          Management of complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Potential complications that must be anticipated include [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seizures and status epilepticus, which should be treated aggressively. There is insufficient evidence to support or refute routine use of antiseizure medications for the primary or secondary prevention of seizures in patients with viral encephalitis [
         <a href="#rid3">
          3
         </a>
         ]. We typically treat with antiseizure medications only if the child has clinical or electroencephalographic evidence of seizures. In most of these cases, ongoing treatment is necessary, at least through the acute phase of illness. (See
         <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">
          "Management of convulsive status epilepticus in children", section on 'Emergency antiseizure treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cerebral edema. (See
         <a class="medical medical_review" href="/z/d/html/6077.html" rel="external">
          "Elevated intracranial pressure (ICP) in children: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106112.html" rel="external">
          "Elevated intracranial pressure (ICP) in children: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluid and electrolyte disturbance (eg, the syndrome of inappropriate antidiuretic hormone secretion [SIADH]). (See
         <a class="medical medical_review" href="/z/d/html/2357.html" rel="external">
          "Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abrupt cardiac and respiratory arrest of central origin. (See
         <a class="medical medical_review" href="/z/d/html/6393.html" rel="external">
          "Initial assessment and stabilization of children with respiratory or circulatory compromise"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          EMPIRIC ANTIMICROBIAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Empiric antimicrobial treatment is warranted in children who present with suspected encephalitis (eg, fever, seizures, decreased or altered mental status, cerebrospinal fluid [CSF] pleocytosis, neuroimaging and/or electroencephalogram findings not attributable to another identified cause). In most cases, initial empiric antimicrobial coverage includes intravenous (IV)
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         for potential herpes simplex virus (HSV) infection and empiric antibiotics (eg,
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         and a third-generation cephalosporin) for potential bacterial central nervous system (CNS) infection (
         <a class="graphic graphic_table graphicRef51779" href="/z/d/graphic/51779.html" rel="external">
          table 2
         </a>
         ). Empiric coverage for other potential infectious causes (eg, influenza,
         <em>
          Mycoplasma pneumonia
         </em>
         , cat scratch disease, Rocky Mountain spotted fever [RMSF], ehrlichiosis, Q fever) is individualized based on the season, exposures, geographic region, and presenting symptoms. Antimicrobial therapy should be started as soon as possible, and, whenever possible, appropriate specimens should be collected prior to initiating antimicrobial therapy.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Empiric acyclovir
         </span>
         <span class="headingEndMark">
          —
         </span>
         The indications for empiric
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         in neonates are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6040.html" rel="external">
          "Neonatal herpes simplex virus infection: Management and prevention", section on 'Indications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106744.html" rel="external">
          "The febrile infant (29 to 90 days of age): Management", section on 'Ill-appearing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/134347.html" rel="external">
          "The febrile neonate (28 days of age or younger): Outpatient evaluation and initial management", section on 'Ill-appearing'
         </a>
         .)
        </p>
        <p>
         For infants and children beyond the neonatal period who present with suspected encephalitis, we recommend prompt initiation of IV
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         pending viral studies [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         HSV encephalitis can be a devastating infection. The majority of survivors have neurologic deficits even when appropriately treated [
         <a href="#rid5">
          5,6
         </a>
         ]. Several small randomized controlled trials in pediatric and adult patients found that antiviral therapy for HSV encephalitis reduces mortality [
         <a href="#rid7">
          7-11
         </a>
         ]. Initial placebo-controlled trials found vidarabine reduced mortality from approximately 70 to 30 percent [
         <a href="#rid7">
          7,8
         </a>
         ]. Subsequent trials found lower mortality with
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         compared with vidarabine [
         <a href="#rid9">
          9-11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8278.html" rel="external">
          "Herpes simplex virus type 1 encephalitis", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dose of
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         varies depending on age [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         &gt;28 days to &lt;3 months – 20 mg/kg per dose IV every eight hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥3 months to &lt;12 years – 10 to 15 mg/kg per dose IV every eight hours; an increased dose (20 mg/kg per dose every eight hours) is approved by the US Food and Drug Administration for the treatment of HSV encephalitis in this age group, but the risk of nephrotoxicity and encephalopathy may be increased; consultation with an infectious disease or pharmacology specialist may be warranted if administered with other nephrotoxic drugs or weight-based dosing exceeds 800 mg per dose [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥12 years – 10 mg/kg per dose IV every eight hours.
        </p>
        <p>
        </p>
        <p>
         Shortages of IV
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         have occurred. If IV acyclovir is not available, alternative agents must be used. Specific recommendations are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/8332.html" rel="external">
          "Acyclovir: An overview", section on 'If there is an acyclovir shortage'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The duration of empiric
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         therapy depends upon laboratory results:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HSV confirmed or probable
         </strong>
         – If HSV polymerase chain reaction (PCR) from CSF or another site is positive,
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         should be continued for 21 days [
         <a href="#rid14">
          14
         </a>
         ]. Lumbar puncture should be performed near the end of acyclovir treatment to ensure that HSV PCR is negative; acyclovir therapy should be continued if CSF HSV PCR remains positive. (See
         <a class="medical medical_review" href="/z/d/html/6040.html" rel="external">
          "Neonatal herpes simplex virus infection: Management and prevention", section on 'Duration of therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8278.html" rel="external">
          "Herpes simplex virus type 1 encephalitis", section on 'Discontinuation of therapy based on PCR results'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HSV PCR is negative
         </strong>
         – For patients in whom HSV PCR is negative, the decision to continue
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         therapy must be individualized. If there are strong clinical indicators of HSV encephalitis (eg, temporal spikes on electroencephalogram or temporal lobe involvement on imaging), repeat lumbar puncture may be warranted to exclude the possibility of a false-negative result on initial testing [
         <a href="#rid5">
          5,15,16
         </a>
         ]. Repeat lumbar puncture also may be warranted in patients with severe neurologic dysfunction even in the absence of clinical indicators of HSV, particularly if no specific alternative etiology has been identified. Additional factors to consider in the decision to continue or discontinue acyclovir therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8278.html" rel="external">
          "Herpes simplex virus type 1 encephalitis", section on 'Discontinuation of therapy based on PCR results'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Empiric antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations and CSF indices of bacterial meningitis and viral encephalitis overlap (
         <a class="graphic graphic_table graphicRef76324" href="/z/d/graphic/76324.html" rel="external">
          table 4
         </a>
         ). Given the serious consequences of delayed treatment for bacterial meningitis, the usual practice is to initiate empiric antibiotic therapy pending cultures in most patients who present with clinical findings suggestive of encephalitis (eg, fever, decreased or altered mental status, seizures, and CSF pleocytosis). Empiric treatment for bacterial meningitis usually consists of
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         <strong>
          plus
         </strong>
         a third-generation cephalosporin (
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">
          cefotaxime
         </a>
         ). Antibiotics can be discontinued after 48 hours if cultures remain negative. Some experts advise discontinuing vancomycin sooner in cases with low suspicion for bacterial meningitis if Gram stain and molecular testing for
         <em>
          Streptococcus pneumoniae
         </em>
         (eg, on multiplex meningitis/encephalitis PCR panel) are negative [
         <a href="#rid17">
          17,18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6010.html" rel="external">
          "Bacterial meningitis in children older than one month: Treatment and prognosis", section on 'Empiric therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Other empiric therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Empiric therapy also may be indicated for other infectious causes of encephalitis that are suspected based on epidemiologic or clinical information (
         <a class="graphic graphic_table graphicRef57122" href="/z/d/graphic/57122.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_table graphicRef73833" href="/z/d/graphic/73833.html" rel="external">
          table 6
         </a>
         and
         <a class="graphic graphic_table graphicRef71744" href="/z/d/graphic/71744.html" rel="external">
          table 7
         </a>
         ) [
         <a href="#rid15">
          15
         </a>
         ]. Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Mycoplasma pneumoniae
         </em>
         – A prodrome of fevers and respiratory symptoms prior to onset of neurologic symptoms may suggest
         <em>
          M. pneumoniae
         </em>
         ; however, respiratory symptoms may be less prominent in some patients. The diagnosis is confirmed with PCR and/or serology. Empiric therapy typically consists of a macrolide antibiotic (eg,
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6070.html" rel="external">
          "
          <i>
           Mycoplasma pneumoniae
          </i>
          infection in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Influenza – Influenza infection may be suggested based upon the constellation of symptoms in the appropriate season. Patients with encephalitis due to suspected influenza should have appropriate testing performed. Treatment for seasonal influenza in children is summarized in the table (
         <a class="graphic graphic_table graphicRef70571" href="/z/d/graphic/70571.html" rel="external">
          table 8
         </a>
         ) and discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cat scratch disease (
         <em>
          Bartonella henselae
         </em>
         ) – Cat scratch disease may be suspected based upon reported exposure to cats (particularly kittens) and other clinical findings (ie, lymphadenopathy). The diagnosis is confirmed with serology. Empiric therapy consists of
         <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">
          doxycycline
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         plus
         <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">
          rifampin
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/5530.html" rel="external">
          "Treatment of cat scratch disease", section on 'Neurologic and ocular manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RMSF (
         <em>
          Rickettsia rickettsia
         </em>
         ) – RMSF may be suspected based upon suggestive clinical findings (maculopapular or petechial rash, particularly with centripetal spread (
         <a class="graphic graphic_picture graphicRef58061" href="/z/d/graphic/58061.html" rel="external">
          picture 1
         </a>
         )) in the setting of exposure to ticks in an endemic region (North, Central, and South America as well as southeastern and south-central states in the United States) (
         <a class="graphic graphic_figure graphicRef68225" href="/z/d/graphic/68225.html" rel="external">
          figure 1
         </a>
         ). The diagnosis is confirmed with serology and/or PCR. Empiric therapy consists of
         <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">
          doxycycline
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/7904.html" rel="external">
          "Clinical manifestations and diagnosis of Rocky Mountain spotted fever"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7912.html" rel="external">
          "Treatment of Rocky Mountain spotted fever"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ehrlichiosis – Clinical and epidemiologic clues to ehrlichial infections (human monocytotropic ehrlichiosis [
         <em>
          Ehrlichia chaffeensis
         </em>
         ] and human granulocytotropic ehrlichiosis [
         <em>
          Anaplasma phagocytophilum
         </em>
         ]) include exposure to ticks in endemic regions (
         <a class="graphic graphic_figure graphicRef72124 graphicRef118614" href="/z/d/graphic/72124.html" rel="external">
          figure 2A-B
         </a>
         ), headache, rash, leukopenia, thrombocytopenia, characteristic blood smear (
         <a class="graphic graphic_picture graphicRef71396 graphicRef60471" href="/z/d/graphic/71396.html" rel="external">
          picture 2A-B
         </a>
         ), and elevated transaminases. The diagnosis is confirmed with serology. Empiric therapy consists of
         <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">
          doxycycline
         </a>
         (same dosing as for RMSF). (See
         <a class="medical medical_review" href="/z/d/html/7907.html" rel="external">
          "Human ehrlichiosis and anaplasmosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Q fever – Exposure to farm animals (eg, sheep, goats, particularly placental tissue, parturient fluids, newborn animals) may suggest Q fever. The diagnosis is confirmed with serology and/or PCR. Empiric treatment consists of
         <a class="drug drug_pediatric" data-topicid="13255" href="/z/d/drug information/13255.html" rel="external">
          doxycycline
         </a>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          THERAPY FOR SPECIFIC VIRUSES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific treatment options, when available, for the more common causes of viral encephalitis in children and adolescents are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enteroviruses and parechoviruses (see
         <a class="medical medical_review" href="/z/d/html/2693.html" rel="external">
          "Enterovirus and parechovirus infections: Clinical features, laboratory diagnosis, treatment, and prevention", section on 'Treatment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Herpes simplex virus (HSV) (see
         <a class="medical medical_review" href="/z/d/html/8278.html" rel="external">
          "Herpes simplex virus type 1 encephalitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6040.html" rel="external">
          "Neonatal herpes simplex virus infection: Management and prevention", section on 'Initial antiviral therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Influenza virus (see
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management", section on 'Antiviral therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arboviruses (see
         <a class="medical medical_review" href="/z/d/html/1293.html" rel="external">
          "Arthropod-borne encephalitides"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1282.html" rel="external">
          "Treatment and prevention of West Nile virus infection"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Epstein-Barr virus (see
         <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">
          "Clinical manifestations and treatment of Epstein-Barr virus infection", section on 'Treatment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cytomegalovirus (see
         <a class="medical medical_review" href="/z/d/html/5965.html" rel="external">
          "Overview of cytomegalovirus infections in children", section on 'Treatment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Human herpesvirus 6 (see
         <a class="medical medical_review" href="/z/d/html/5969.html" rel="external">
          "Human herpesvirus 6 infection in children: Clinical manifestations, diagnosis, and treatment", section on 'Treatment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Varicella (see
         <a class="medical medical_review" href="/z/d/html/8336.html" rel="external">
          "Treatment of varicella (chickenpox) infection", section on 'Individuals with complications'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          ADJUNCTIVE THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on the available evidence, we suggest
         <strong>
          not
         </strong>
         routinely treating children with encephalitis with adjunctive therapies, including glucocorticoids, plasmapheresis, intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         (IVIG), interferon alfa, and therapeutic hypothermia [
         <a href="#rid2">
          2,15,19-22
         </a>
         ]. Although observational reports have described beneficial effects of some of these adjunctive therapies in limited settings, the reports vary and a clear benefit has not been established [
         <a href="#rid2">
          2,15
         </a>
         ].
        </p>
        <p>
         An exception is the child with viral encephalitis who has an underlying humoral immunodeficiency (agammaglobulinemia, hypogammaglobulinemia), for whom replacement
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         therapy is appropriate, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16132.html" rel="external">
          "Common variable immunodeficiency in children", section on 'Immune globulin'
         </a>
         .)
        </p>
        <p>
         In addition, immune-modifying therapies (eg, glucocorticoids,
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         ) are routinely used in the management of the following conditions, which can present with clinical, laboratory, and imaging findings similar to those of acute infectious encephalitis. These conditions are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute disseminated encephalomyelitis (see
         <a class="medical medical_review" href="/z/d/html/6208.html" rel="external">
          "Acute disseminated encephalomyelitis (ADEM) in children: Treatment and prognosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune encephalitis (see
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coronavirus disease 2019 (COVID-19)-related multisystem inflammatory syndrome in children (MIS-C) (see
         <a class="medical medical_review" href="/z/d/html/129614.html" rel="external">
          "COVID-19: Multisystem inflammatory syndrome in children (MIS-C) management and outcome", section on 'Immunomodulatory therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis of viral encephalitis varies depending upon the age of the patient, neurologic findings at the time of presentation, and pathogen. Poor outcome is associated with the following factors [
         <a href="#rid23">
          23-28
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coma, convulsion, or focal neurologic findings in the acute phase
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Young age (&lt;5 years)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Need for intensive care
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Herpes simplex encephalitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diffusion restriction on magnetic resonance imaging
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3104877">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overall risk of death in childhood encephalitis ranges from 0 to 7 percent [
         <a href="#rid23">
          23,24,29,30
         </a>
         ]. However, mortality is increased with specific pathogens (eg, in herpes simplex encephalitis and eastern equine encephalitis). (See
         <a class="medical medical_review" href="/z/d/html/8278.html" rel="external">
          "Herpes simplex virus type 1 encephalitis", section on 'Outcomes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1293.html" rel="external">
          "Arthropod-borne encephalitides", section on 'Eastern equine encephalitis virus'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3104883">
         <span class="h2">
          Neurologic sequelae
         </span>
         <span class="headingEndMark">
          —
         </span>
         In self-limited cases, lethargy and coma gradually improve over days to weeks [
         <a href="#rid29">
          29
         </a>
         ]. Focal deficits resolve more slowly. In a series of 71 patients from a single institution, 24 children (34 percent) made a complete recovery within 6 to 12 months [
         <a href="#rid25">
          25
         </a>
         ]. Persistent neurologic effects may include personality change, behavior disorder (including attention deficit disorder), movement disorder (including tic disorders), intellectual disability, learning disorders, blindness, paresis, ataxia, recurrent headaches, and sleeping problems [
         <a href="#rid25">
          25-27
         </a>
         ].
        </p>
        <p>
         In a study that evaluated neurologic outcomes in 99 children with encephalitis at a mean 35.6 months duration of follow-up, the following findings were noted [
         <a href="#rid31">
          31
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No neurologic sequelae (51 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Learning problems (23 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Developmental delay (19 percent, including 7 percent with global developmental delay)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Behavioral problems (10 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Motor deficit (2 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Visual defects (1 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hearing impairment (1 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bladder spasticity (1 percent)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3105006">
         <span class="h2">
          Outcomes of specific viral pathogens
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Herpes simplex virus (HSV) encephalitis – At least two-thirds of children and adolescents surviving with HSV encephalitis have some form of neurologic debility (eg, seizure disorder, global developmental delay, residual hemiplegia) [
         <a href="#rid5">
          5,6,9,25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The outcome of neonatal HSV central nervous system (CNS) disease is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6040.html" rel="external">
          "Neonatal herpes simplex virus infection: Management and prevention", section on 'Outcome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arboviruses – The outcome of arboviral encephalitis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1293.html" rel="external">
          "Arthropod-borne encephalitides"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enteroviruses – Enteroviral encephalitis generally causes milder clinical disease than other viruses, except when it causes CNS infection in neonates with disseminated disease [
         <a href="#rid25">
          25,32
         </a>
         ]. Enterovirus A71 (EV-A71), which causes epidemics worldwide, is associated with high morbidity and mortality [
         <a href="#rid33">
          33-35
         </a>
         ]. In a retrospective review of 36 patients with EV-A71 CNS and cardiopulmonary failure, 15 died (12 during the acute phase and three during convalescence); 16 of the 21 survivors had severe sequelae (central hypoventilation, dysphagia, limb weakness) [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2694.html" rel="external">
          "Enterovirus and parechovirus infections: Epidemiology and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2693.html" rel="external">
          "Enterovirus and parechovirus infections: Clinical features, laboratory diagnosis, treatment, and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          LONG-TERM FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supportive care, rehabilitation, and monitoring should continue for at least one year after discharge from the hospital [
         <a href="#rid25">
          25
         </a>
         ]. Long-term sequelae of viral encephalitis may not manifest during the acute illness. These include motor incoordination, seizures, strabismus, amblyopia, hearing impairment, and behavioral disturbances [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Hearing evaluation should be performed at the time of or shortly after discharge from the hospital. Children and adolescents who survive encephalitis are at risk for developmental and/or intellectual disability. Developmental surveillance should continue throughout childhood. Neuropsychologic testing may be helpful in identifying neurologic deficits and formulating a treatment plan. (See
         <a class="medical medical_review" href="/z/d/html/6297.html" rel="external">
          "Hearing loss in children: Screening and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/615.html" rel="external">
          "Developmental-behavioral surveillance and screening in primary care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          PREVENTION AND CONTROL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because treatment options for encephalitis are limited, prevention is paramount.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Primary prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary prevention measures include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Handwashing (see
         <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">
          "Infection prevention: Precautions for preventing transmission of infection", section on 'Hand hygiene'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Appropriate identification, monitoring, and treatment of genital herpes simplex virus (HSV) infection during pregnancy to prevent neonatal HSV (see
         <a class="medical medical_review" href="/z/d/html/8340.html" rel="external">
          "Genital herpes simplex virus infection and pregnancy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Routine immunization of infants, children, and adolescents (for measles, mumps, rubella, varicella, influenza) and appropriate immunization of travelers depending upon their destination(s) (eg, Japanese encephalitis vaccine, tick-borne encephalitis virus vaccine) (see
         <a class="medical medical_review" href="/z/d/html/3890.html" rel="external">
          "Immunizations for travel"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insect control and avoidance of mosquito and tick exposure (eg, draining stagnant water, appropriate dress, use of mosquito and tick repellants, mosquito netting, looking for ticks after hiking, etc) (see
         <a class="medical medical_review" href="/z/d/html/4085.html" rel="external">
          "Prevention of arthropod and insect bites: Repellents and other measures"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Appropriate viral screening of blood products (eg, West Nile virus) (see
         <a class="medical medical_review" href="/z/d/html/7946.html" rel="external">
          "Blood donor screening: Laboratory testing", section on 'Viruses'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Infection control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who are hospitalized with encephalitis are usually placed on droplet and contact precautions at the time of admission. Isolation precautions can be changed if and when a specific pathogen is identified. Consultation with the hospital infection control practitioner or local health department may be helpful in making decisions regarding isolation precautions and/or evaluation or treatment of contacts. (See
         <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">
          "Infection prevention: Precautions for preventing transmission of infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3113607161">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109959.html" rel="external">
          "Society guideline links: Infectious encephalitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2614782483">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/17213.html" rel="external">
          "Patient education: Encephalitis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview table
         </strong>
         – A quick summary of the management of suspected encephalitis in children is provided in the table (
         <a class="graphic graphic_table graphicRef51779" href="/z/d/graphic/51779.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
         – Potential complications include status epilepticus, cerebral edema, fluid and electrolyte disturbance, and cardiorespiratory failure. Patients with severe encephalitis (ie, those with seizures, cardiorespiratory compromise, coma, or severe neurologic compromise) should be cared for in an intensive care unit with close cardiorespiratory monitoring and careful attention to neurologic status, fluid balance, and electrolyte status. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Empiric antimicrobial therapy
         </strong>
         – All children who present with clinical findings that are consistent with encephalitis (ie, fever, seizures, decreased or altered mental status, cerebrospinal fluid [CSF] pleocytosis, abnormal neuroimaging and/or electroencephalogram findings not attributable to another identified cause) should receive prompt empiric antimicrobial treatment. Whenever possible, appropriate specimens should be collected prior to initiating antimicrobial therapy. (See
         <a class="local">
          'Empiric antimicrobial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acyclovir
         </strong>
         – For all children who present with suspected encephalitis, we recommend prompt initiation of
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         pending viral studies (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Empiric acyclovir'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8278.html" rel="external">
          "Herpes simplex virus type 1 encephalitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6040.html" rel="external">
          "Neonatal herpes simplex virus infection: Management and prevention", section on 'Initial antiviral therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antibiotics
         </strong>
         – Empiric treatment for bacterial meningitis (
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         <strong>
          plus
         </strong>
         a third-generation cephalosporin [
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">
          cefotaxime
         </a>
         ]) pending bacterial cultures is also usually warranted since, in most cases, bacterial meningitis cannot be excluded initially. (See
         <a class="local">
          'Empiric antibiotics'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6010.html" rel="external">
          "Bacterial meningitis in children older than one month: Treatment and prognosis", section on 'Empiric therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other empiric therapy
         </strong>
         – Empiric therapy also may be indicated for other infectious causes of encephalitis that are suspected based on epidemiologic or clinical information (
         <a class="graphic graphic_table graphicRef57122" href="/z/d/graphic/57122.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_table graphicRef73833" href="/z/d/graphic/73833.html" rel="external">
          table 6
         </a>
         and
         <a class="graphic graphic_table graphicRef71744" href="/z/d/graphic/71744.html" rel="external">
          table 7
         </a>
         ). (See
         <a class="local">
          'Other empiric therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The prognosis of viral encephalitis varies depending upon the age of the patient, neurologic findings at the time of presentation, and pathogen. The overall risk of death in childhood encephalitis ranges from 0 to 7 percent; however, the risk is increased with specific pathogens (eg, in herpes simplex encephalitis and eastern equine encephalitis). Long-term neurologic sequelae are common. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term follow-up
         </strong>
         – Survivors of childhood encephalitis should be monitored for long-term sequelae, including motor incoordination, seizures, strabismus, amblyopia, hearing impairment, and behavioral disturbances. Hearing evaluation should be performed at the time of or shortly after discharge from the hospital. Developmental surveillance should continue throughout childhood. (See
         <a class="local">
          'Long-term follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4132101631">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Paul Krogstad, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Venkatesan A, Tunkel AR, Bloch KC, et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis 2013; 57:1114.
          </a>
         </li>
         <li class="breakAll">
          Bronstein DE, Glaser CA. Encephalitis and meningoencephalitis. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 8th ed, Cherry J, Demmler-Harrison GJ, Steinbach WJ, Kaplan SL, Hotez PJ (Eds), Elsevier Saunders, Philadelphia 2019. p.361.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pandey S, Rathore C, Michael BD. Antiepileptic drugs for the primary and secondary prevention of seizures in viral encephalitis. Cochrane Database Syst Rev 2016; :CD010247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson C, Kneen R, Riordan A, et al. Encephalitis in children. Arch Dis Child 2012; 97:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elbers JM, Bitnun A, Richardson SE, et al. A 12-year prospective study of childhood herpes simplex encephalitis: is there a broader spectrum of disease? Pediatrics 2007; 119:e399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitley RJ, Kimberlin DW. Herpes simplex encephalitis: children and adolescents. Semin Pediatr Infect Dis 2005; 16:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitley RJ, Nahmias AJ, Soong SJ, et al. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics 1980; 66:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitley RJ, Soong SJ, Dolin R, et al. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med 1977; 297:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986; 314:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitley R, Arvin A, Prober C, et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991; 324:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sköldenberg B, Forsgren M, Alestig K, et al. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet 1984; 2:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimberlin DW. Acyclovir Dosing in the Neonatal Period and Beyond. J Pediatric Infect Dis Soc 2013; 2:179.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Non-HIV antiviral drugs. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.919.
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Herpes simplex. In: Red Book: 2018-2021 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2018. p.437.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weil AA, Glaser CA, Amad Z, Forghani B. Patients with suspected herpes simplex encephalitis: rethinking an initial negative polymerase chain reaction result. Clin Infect Dis 2002; 34:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jhaveri R. The Time Has Come to Stop Using Vancomycin as Part of Empiric Therapy for Meningitis. J Pediatric Infect Dis Soc 2019; 8:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackley ER, Tchou MJ, Press CA, et al. AKI In Suspected Meningitis/Encephalitis May Be "Avoidable Kidney Injury". Hosp Pediatr 2021; 11:e167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoke CH Jr, Vaughn DW, Nisalak A, et al. Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus. J Infect Dis 1992; 165:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makhoul B, Braun E, Herskovitz M, et al. Hyperimmune gammaglobulin for the treatment of West Nile virus encephalitis. Isr Med Assoc J 2009; 11:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon T, Dung NM, Wills B, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 2003; 361:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawano G, Iwata O, Iwata S, et al. Determinants of outcomes following acute child encephalopathy and encephalitis: pivotal effect of early and delayed cooling. Arch Dis Child 2011; 96:936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rautonen J, Koskiniemi M, Vaheri A. Prognostic factors in childhood acute encephalitis. Pediatr Infect Dis J 1991; 10:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler A, Stödberg T, Eriksson M, Wickström R. Childhood encephalitis in Sweden: etiology, clinical presentation and outcome. Eur J Paediatr Neurol 2008; 12:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowler A, Stödberg T, Eriksson M, Wickström R. Long-term outcomes of acute encephalitis in childhood. Pediatrics 2010; 126:e828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaeli O, Kassis I, Shachor-Meyouhas Y, et al. Long-term motor and cognitive outcome of acute encephalitis. Pediatrics 2014; 133:e546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang IJ, Lee PI, Huang LM, et al. The correlation between neurological evaluations and neurological outcome in acute encephalitis: a hospital-based study. Eur J Paediatr Neurol 2007; 11:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillai SC, Hacohen Y, Tantsis E, et al. Infectious and autoantibody-associated encephalitis: clinical features and long-term outcome. Pediatrics 2015; 135:e974.
          </a>
         </li>
         <li class="breakAll">
          Willoughby RE, Long SS. Encephalitis, meningoencephalitis, acute disseminated encephalomyelitis, and acute necrotizing encephalopathy. In: Principles and Practice of Pediatric Infectious Diseases, 2nd ed, Long SS, Pickering LK, Prober CG (Eds), Churchill Livingstone, New York 2008. p.310.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolski H, Ford-Jones EL, Richardson S, et al. Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995. Clin Infect Dis 1998; 26:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rismanchi N, Gold JJ, Sattar S, et al. Neurological Outcomes After Presumed Childhood Encephalitis. Pediatr Neurol 2015; 53:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fowlkes AL, Honarmand S, Glaser C, et al. Enterovirus-associated encephalitis in the California encephalitis project, 1998-2005. J Infect Dis 2008; 198:1685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang LY, Hsia SH, Wu CT, et al. Outcome of enterovirus 71 infections with or without stage-based management: 1998 to 2002. Pediatr Infect Dis J 2004; 23:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez-Vélez CM, Anderson MS, Robinson CC, et al. Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. Clin Infect Dis 2007; 45:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999; 341:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherry JD. Recognition and management of encephalitis in children. Adv Exp Med Biol 2009; 634:53.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5977 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23861361" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23861361" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27209627" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Antiepileptic drugs for the primary and secondary prevention of seizures in viral encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21715390" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Encephalitis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17272602" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A 12-year prospective study of childhood herpes simplex encephalitis: is there a broader spectrum of disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15685145" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Herpes simplex encephalitis: children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7001331" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Vidarabine therapy of neonatal herpes simplex virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/195208" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3001520" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Vidarabine versus acyclovir therapy in herpes simplex encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1988829" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6148470" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26619466" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Acyclovir Dosing in the Neonatal Period and Beyond.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26619466" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Acyclovir Dosing in the Neonatal Period and Beyond.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26619466" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Acyclovir Dosing in the Neonatal Period and Beyond.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18582201" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11915008" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Patients with suspected herpes simplex encephalitis: rethinking an initial negative polymerase chain reaction result.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30380088" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The Time Has Come to Stop Using Vancomycin as Part of Empiric Therapy for Meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34244336" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : AKI In Suspected Meningitis/Encephalitis May Be "Avoidable Kidney Injury".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1313068" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19544704" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hyperimmune gammaglobulin for the treatment of West Nile virus encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12642049" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20554765" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Determinants of outcomes following acute child encephalopathy and encephalitis: pivotal effect of early and delayed cooling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1906597" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Prognostic factors in childhood acute encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18313340" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Childhood encephalitis in Sweden: etiology, clinical presentation and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20876179" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Long-term outcomes of acute encephalitis in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24534397" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Long-term motor and cognitive outcome of acute encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17240177" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The correlation between neurological evaluations and neurological outcome in acute encephalitis: a hospital-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25802349" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Infectious and autoantibody-associated encephalitis: clinical features and long-term outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25802349" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Infectious and autoantibody-associated encephalitis: clinical features and long-term outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9502462" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Etiology of acute childhood encephalitis at The Hospital for Sick Children, Toronto, 1994-1995.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26220354" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Neurological Outcomes After Presumed Childhood Encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18959496" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Enterovirus-associated encephalitis in the California encephalitis project, 1998-2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15071287" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Outcome of enterovirus 71 infections with or without stage-based management: 1998 to 2002.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17879907" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10498487" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19280848" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Recognition and management of encephalitis in children.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
